Building Scalable, Reliable AAV Gene Therapy Manufacturing

August 10, 2026 - 07:34

Gene therapy is at a turning point. The FDA recently granted a regenerative medicine advanced therapy designation to ELVECTA, a candidate for a rare genetic disorder. That designation speeds up development, but it also puts a spotlight on something less glamorous: manufacturing. Emmanuel Abate, a senior director at Cytiva, says the real bottleneck is not the science of the vector itself. It is the ability to make enough of it, safely, at scale.

One of the biggest technical hurdles is encapsidated host cell DNA. During production, empty or partially filled viral capsids can pick up fragments of DNA from the producer cells. That leftover genetic material is a safety concern because it could, in theory, trigger an immune response or carry unintended sequences into a patient. The industry has known about this for years, but the detection and removal methods have lagged behind the demand for larger batches.

Abate points to advanced analytics as a way forward. Instead of relying on end-product testing alone, newer platforms can measure host cell DNA contamination in real time, during the purification process. That shift from reactive to proactive quality control is critical. If a batch is going to fail, you want to know early, not after weeks of production.

There is also the question of platform design. Traditional adherent cell culture works for small clinical trials, but it does not scale well. Suspension-based systems, along with single-use bioreactors, offer more flexibility. They allow manufacturers to increase output without rebuilding a facility. Abate argues that these platforms, combined with better in-line sensors and process automation, could bring down the cost per dose and make gene therapies more accessible.

The FDA's designation for ELVECTA is a positive signal, but it does not solve the manufacturing puzzle. The companies that will succeed are the ones that treat production as a core part of the therapy, not an afterthought. That means investing in better characterization tools, tighter process controls, and a workforce that understands both biology and engineering. The goal is not just to make a therapy that works in a few patients, but to make one that can be produced reliably for thousands.